Gilead Sciences recently announced its decision to withdraw Trodelvy from the market as a treatment for bladder cancer, following disappointing results from its confirmatory TROPiCS-04 clinical trial. This marks a notable shift for a drug that initially showed promise in shrinking tumors and
Sage Therapeutics, a biopharmaceutical company specializing in brain health medications, finds itself at a pivotal moment. Facing financial strains and developmental hurdles, the company is taking significant steps to realign its strategy, including layoffs, leadership changes, and focusing on
Nuclera, a trailblazing biotechnology company specializing in protein expression and purification, recently raised $75 million in a fresh funding round. This significant financial boost is intended to support the commercialization and global deployment of Nuclera’s eProtein Discovery™ system. The
In the fast-paced and highly competitive world of pharmaceuticals, retaining top talent is no small feat. Ferring Pharmaceuticals, a Swiss biopharmaceutical company, has found a winning strategy by focusing on holistic worker well-being and steadfastly committing to diversity, equity, and inclusion
Ellorarxine, a groundbreaking drug compound developed by Nevrargenics, is showing remarkable promise in the treatment of Amyotrophic Lateral Sclerosis (ALS) and has recently received approval from the MHRA to advance to human trials. This news brings a glimmer of hope to the over 5,000 individuals
In the fast-paced world of biopharmaceuticals, Competitive Intelligence (CI) is indispensable for strategic decision-making and maintaining a competitive edge. As the sector evolves, understanding how to optimize CI for maximum strategic value becomes increasingly crucial. This article explores
The recent reaffirmation of Piper Sandler's Overweight rating for Sutro Biopharma (NASDAQ: STRO) has sparked investor interest. While the company's shares have experienced significant volatility, the solid clinical advancements and strategic partnerships suggest potential growth. Analyzing Sutro’s
Innovation in biotechnology, particularly within the realm of cell therapy, hinges significantly on the expertise of regulatory professionals. These experts are instrumental in navigating complex regulatory landscapes and ensuring that scientific advances transition into viable, market-ready
RTI Surgical has recently taken a significant step in enhancing its capabilities in regenerative medicine through the strategic acquisition of Collagen Solutions. This move is set to expand RTI’s portfolio in biomaterials, which further establishes the company as a leader in the biomedical sector.
The market for gene therapies is predicted to surge from $9 billion in 2023 to $23.9 billion in 2028, according to MarketsandMarkets. With such rapid growth, it has become increasingly evident that having an effective analytical testing strategy is crucial for the successful development and
